The goals of the Radiation Biology &Imaging (RBI) Program remain unchanged since the last review of the ACC Core Grant. The RBI program seeks to improve the outcome of patients through the advanced understanding of how ionizing and non-ionizing radiation interacts with cancer and normal tissues. Through the RBI Program, investigators from diverse backgrounds and multiple Departments within the School of Medicine, Veterinary School and the School of Engineering, are brought together to identify the molecular and physiological determinants of radiation and PDT response in tumors. New areas of focus developed in the last two years include the use of nanomaterials to deliver therapeutic and imaging agents to tumors and the use of sophisticated imaging and radiation delivery approaches to better define and evaluate targets and treat tumors with the lowest possible damage to normal tissues. These new efforts have been strengthened with a substantial recruitment effort of new members into the RBI program. The programmatic goals are: 1. to understand the basic molecular mechanisms underlying the cellular response to radiation and to develop molecular targets for manipulating the response of tumors to drugs and ionizing radiation; 2. to develop clinical trials for photodynamic therapy and understand the underlying molecular and physiologic mechanisms that underlie its use; 3. to develop mechanisms to test and validate invasive and non-invasive methods for measuring tumor oxygenation and metabolic status; 4. to study the molecular events in the response to DNA damage by ionizing radiation;and 5. to develop imaging techniques that are related to the delivery and underlying mechanisms of radiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-37
Application #
8567186
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$124,028
Indirect Cost
$90,210
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Zhang, Zi; Brown, Justin C; O'Malley Jr, Bert W et al. (2016) Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. Support Care Cancer 24:2333-40

Showing the most recent 10 out of 848 publications